SLC5A2 and diabetic kidney disease: Although some studies using diabetic animal models demonstrated that long-term treatment with SGLT2 inhibitors improved glucose homeostasis and maintained pancreatic beta cell function [23–25], the beneficial effects of dapagliflozin on the renal RAS activation in an animal model of type 2 diabetes with diabetic nephropathy have not been determined.